Universal cell therapy product and use thereof
Номер патента: CA3189963A1
Опубликовано: 03-02-2022
Автор(ы): Bruno Robert, Christian Jorgensen, Francisco Javier Hernandez, Jessy PRESUMEY, Martin VILLALBA, Pierre Martineau
Принадлежит: Centre Hospitalier Universitaire de Montpellier CHUM, Icm Institut De Cancerologie De Montpellier, Institut National de la Sante et de la Recherche Medicale INSERM, Universite de Montpellier I
Опубликовано: 03-02-2022
Автор(ы): Bruno Robert, Christian Jorgensen, Francisco Javier Hernandez, Jessy PRESUMEY, Martin VILLALBA, Pierre Martineau
Принадлежит: Centre Hospitalier Universitaire de Montpellier CHUM, Icm Institut De Cancerologie De Montpellier, Institut National de la Sante et de la Recherche Medicale INSERM, Universite de Montpellier I
Реферат: The present invention relates to the field of therapeutic treatment, particularly of cell therapy based on CD 16+ cells and NK (Natural Killer) cells. In particular, the invention relates to a pharmaceutical composition comprising a CD 16+ cell, a NK cell or a NK cell precursor, in combination with a recombinant polypeptide comprising a modified Fc region, in particular a modified CH2 domain. More particularly, the invention relates to a composition comprising a CD 16+ cell and/or a NK cell, in combination with a recombinant polypeptide capable of binding to the Fc?RIII (CD 16) surface protein, wherein the recombinant polypeptide is non-covalently bound to the Fc?RIII (CD 16) surface protein expressed by the CD 16+ cell, and wherein said recombinant polypeptide comprises: (i) a modified CH2 domain of a wild-type human IgGl, bound, optionally through a linker, to (ii) a ligand binding domain, wherein the ligand binding domain comprises a sequence capable of binding to a target ligand; wherein the modified CH2 domain is characterized by comprising mutations S239D and I332E with respect to the CH2 domain of a wild-type human IgG1, and wherein said CH2 domain of a wild-type human IgG1 is represented by SEQ ID NO 1, and comprises sequence positions 231-340, according to the EU numbering.
Armed nk cells for universal cell therapy
Номер патента: US20240293455A1. Автор: Bruno Robert,Pierre Martineau,Christian Jorgensen,Martin VILLALBA,Jessy PRESUMEY,Francisco Javier Harnandez. Владелец: Center Hospitalier Universitaire De Montpellier Chum. Дата публикации: 2024-09-05.